OsteonecrosisPhase 1/2NCT04233125
Core Decompression With or Without Cement Packing for ONFH
A Phase 1/2 study testing Core Decompression and PMMA augmentation in people with Osteonecrosis, run by University of Minnesota.
Trial summary
Osteonecrosis of the femoral head (ONFH) is difficult to treat as collapse frequently occurs after core decompression (CD). This may be due to the failure to provide structural support during revascularization and healing. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Osteonecrosis
- What is being tested?
- Core Decompression and PMMA augmentation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 1997to 1 Jan 2008
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging
Who cannot join
- pre-existing collapse, subchondral fracture or degenerative changes of the hip
About this study
Official title: A Randomized Controlled Trial of Core Decompression With or Without Cement Packing for Osteonecrosis of the Femoral Head - Long Term Results
Osteonecrosis of the femoral head (ONFH) is difficult to treat as collapse frequently occurs after core decompression (CD). This may be due to the failure to provide structural support during revascularization and healing. Reports of polymethylmethacrylate (PMMA) packing of the femoral head after CD for ONFH have noted favorable results. This study was undertaken to determine whether the addition of PMMA packing to CD provides any benefit to progression-free survival (PFS) and conversion to total hip arthroplasty-free survival (CFS). Secondary objectives were to assess for differences in functional outcomes and predictive factors for progression of the disease.
Read the detailed description
A prospective randomized controlled trial comparing the results of CD vs. CD + PMMA packing in pre-collapse ONFH was set up.
Consecutive symptomatic patients aged >14 years with Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging were enrolled in this study.
Exclusion criteria were pre-existing collapse, sub-chondral fracture or degenerative changes of the hip.
After obtaining informed written consent, patients are asked to complete the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and a health status questionnaire Short Form-36 (SF-36).
The femoral heads enrolled into the study are randomized using a computer-generated card draw system to one of following: core decompression (CD) or core decompression with PMMA cement packing (CD + PMMA).
Allocation concealment was practiced with the use of opaque envelopes. Patients with bilateral involvement who had been randomized to one treatment modality for one femoral head were automatically selected to receive the other treatment modality for the contralateral femoral head.
Blinding of either surgeon or patient is impossible.
The patients were followed up after surgery every 3-4 months for the first 2 years after which the patients were seen annually. Completed questionnaires and radiographs were obtained at each visit.
Statistical Analysis The date of index procedure (CD or CD + PMMA) was used as start date for the purpose of statistical analysis. Progression Free Survival was defined as the time to radiographic progression and Conversion Free Survival (CFS) as the time to a THA. In case of patients who did not have radiographic progression, the date of their last follow up or death was used for the analysis. The SAS software will be used for all the analyses. The Log rank and Gerhan-Wilcoxon tests were used to compare Kaplan-Meier survival curves for the time from the date of the index procedure to radiographic progression (subchondral collapse) or conversion to THA for separate groupings based on age at index procedure (<40 , >40 yrs), smoking (Y/N), location (central, medial, lateral), percent involvement (<15% [mild], 15% to 30% [moderate], or >30% [severe]), index of necrotic extent (<40 or >40), and modified index of necrotic extent (<40 or >40). Whenever factors were found to affect the survival curves mainly in the initial year the Gerhan-Wilcoxon test was used as the test of significance. The Kaplan-Meier curves were also compared for the main cohorts of CD vs. CD + PMMA. Cox proportional hazards regression was used to compare factors (age, smoking, location, percent involvement, index of necrotic extent, and modified index of necrotic extent) with regards to their ability to predict the time to progression or revision to THA. Mixed multilevel regression modeling was used to test for group differences in the change in self-rated health survey scores over time from baseline over the post-operative period. The hierarchical linear modeling approach has a number of advantages over traditional repeated measures approaches for modeling change over time, including allowance for missing data and for varying measurement times across subjects. Separate models were generated for SF-36, Harris Hip Score and WOMAC scores over two-year and over 5-year post-operative time periods.
- Conditions
- Osteonecrosis
- Being tested
- Core Decompression, PMMA augmentation
- Keywords
- Femoral Head, Hip, Core Decompression, Polymethlymethacrylate, Cement, Progression, Survival
- Medical subject headings
- Osteonecrosis, Disease Progression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Core DecompressionProcedure or surgery
Core Decompression
PMMA augmentationProcedure or surgery
Polymethylmethacrylate (PMMA) augmentation
| Study group | Role | What they receive |
|---|---|---|
| Core Decompression (CD) Only | Active comparator | Participants in this group receive standard care Receives: Procedure: Core Decompression |
| Added Polymethylmethacrylate (PMMA) | Experimental | Participants in this group receive standard care with an additional treatment Receives: Procedure: Core Decompression; Procedure: PMMA augmentation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as the length of time (reported in months) following surgery that participants have no signs of radiographic progression of femoral head osteonecrosis. Radiographic progression is defined as any degree of flattening or loss of spherical contour of the femoral head as detected on the radiographs or MRI. Appearance of a subchondral fracture (crescent sign) on radiographs or MRI was also considered a sign of progression.
Measured: 5 years
Secondary outcomes (7)
Conversion Free Survival (CFS)
Conversion Free Survival (CFS) is defined as the length of time (reported in months) following surgery that participants are able to live without surgical conversion to total hip arthroplasty (THA).
Measured: 5 years
Mean Harris Hip Score (HHS)
The Harris Hip Score (HHS) is a clinician-based instrument with 4 sub-scales measuring pain severity (44 points), function (47 points), absence of deformity (4 points), and range of motion (5 points). Total score is calculated as a sum of 4 sub-scale scores and ranges from 0-100 with higher scores representing less dysfunction. Three time points will be reported.
Measured: baseline, 2 years post surgery, 5 years post surgery
Change in Harris Hip Score (HHS)
The Harris Hip Score (HHS) is a clinician-based instrument with 4 sub-scales measuring pain severity (44 points), function (47 points), absence of deformity (4 points), and range of motion (5 points). Total score is calculated as a sum of 4 sub-scale scores and ranges from 0-100 with higher scores representing less dysfunction.
Measured: baseline, 2 years post surgery
Mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items), stiffness (2 items), and physical function (17 items). Items are rated on a Likert scale of 0 (extreme) to 4 (none). Raw sub-scale scores are normalized by multiplying each score by 100/96. Total scores are a sum of the normalized sub-scales scores and range 0-100, with higher scores indicating better functioning. Three time points will be reported.
Measured: baseline, 2 years post surgery, 5 years post surgery
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items), stiffness (2 items), and physical function (17 items). Items are rated on a Likert scale of 0 (extreme) to 4 (none). Raw sub-scale scores are normalized by multiplying each score by 100/96. Total scores are a sum of the normalized sub-scales scores and range 0-100, with higher scores indicating better functioning.
Measured: baseline, 2 years post surgery
Mean Short Form-36 (SF-36)
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health, containing 8 scaled sub-scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each sub-scale score is calculated as the weighted sum of the questions in that section, then directly transformed into a 0-100 score using a scoring algorithm. The SF-36 also produces two summary scores, physical component summary and the mental component summary. Lower scores indicated greater disability. Three time points will be reported.
Measured: baseline, 2 years post surgery, 5 years post surgery
Change in Short Form-36 (SF-36)
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health, containing 8 scaled sub-scores: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each sub-scale score is calculated as the weighted sum of the questions in that section, then directly transformed into a 0-100 score using a scoring algorithm. The SF-36 also produces two summary scores, physical component summary and the mental component summary. Lower scores indicated greater disability.
Measured: baseline, 2 years post surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2020
- Study start1 Jan 1997
- Primary completion1 Jan 2005
- Study completion1 Jan 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteonecrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04233125
- Sponsor's protocol ID
- 9604M11032
- Status last verified
- Jan 2020
- First submitted
- 14 Jan 2020
- Last updated
- 18 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Core Decompression With or Without Cement Packing for Osteonecrosis of the Femoral Head - Long Term Results
- ClinicalTrials.gov ID
- NCT04233125
- Acronym / sponsor ID
- 9604M11032
- Conditions
- Osteonecrosis
- Keywords
- Femoral Head, Hip, Core Decompression, Polymethlymethacrylate, Cement, Progression, Survival
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- 1 Jan 1997 (actual)
- Primary completion
- 1 Jan 2005 (actual)
- Study completion
- 1 Jan 2008 (actual)
- First posted
- 18 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteonecrosis of the femoral head (ONFH) is difficult to treat as collapse frequently occurs after core decompression (CD). This may be due to the failure to provide structural support during revascularization and healing. Reports of polymethylmethacrylate (PMMA) packing of the femoral head after CD for ONFH have noted favorable results. This study was undertaken to determine whether the addition of PMMA packing to CD provides any benefit to progression-free survival (PFS) and conversion to total hip arthroplasty-free survival (CFS). Secondary objectives were to assess for differences in functional outcomes and predictive factors for progression of the disease.
Detailed description
A prospective randomized controlled trial comparing the results of CD vs. CD + PMMA packing in pre-collapse ONFH was set up.
Consecutive symptomatic patients aged >14 years with Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging were enrolled in this study.
Exclusion criteria were pre-existing collapse, sub-chondral fracture or degenerative changes of the hip.
After obtaining informed written consent, patients are asked to complete the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and a health status questionnaire Short Form-36 (SF-36).
The femoral heads enrolled into the study are randomized using a computer-generated card draw system to one of following: core decompression (CD) or core decompression with PMMA cement packing (CD + PMMA).
Allocation concealment was practiced with the use of opaque envelopes. Patients with bilateral involvement who had been randomized to one treatment modality for one femoral head were automatically selected to receive the other treatment modality for the contralateral femoral head.
Blinding of either surgeon or patient is impossible.
The patients were followed up after surgery every 3-4 months for the first 2 years after which the patients were seen annually. Completed questionnaires and radiographs were obtained at each visit.
Statistical Analysis The date of index procedure (CD or CD + PMMA) was used as start date for the purpose of statistical analysis. Progression Free Survival was defined as the time to radiographic progression and Conversion Free Survival (CFS) as the time to a THA. In case of patients who did not have radiographic progression, the date of their last follow up or death was used for the analysis. The SAS software will be used for all the analyses. The Log rank and Gerhan-Wilcoxon tests were used to compare Kaplan-Meier survival curves for the time from the date of the index procedure to radiographic progression (subchondral collapse) or conversion to THA for separate groupings based on age at index procedure (<40 , >40 yrs), smoking (Y/N), location (central, medial, lateral), percent involvement (<15% [mild], 15% to 30% [moderate], or >30% [severe]), index of necrotic extent (<40 or >40), and modified index of necrotic extent (<40 or >40). Whenever factors were found to affect the survival curves mainly in the initial year the Gerhan-Wilcoxon test was used as the test of significance. The Kaplan-Meier curves were also compared for the main cohorts of CD vs. CD + PMMA. Cox proportional hazards regression was used to compare factors (age, smoking, location, percent involvement, index of necrotic extent, and modified index of necrotic extent) with regards to their ability to predict the time to progression or revision to THA. Mixed multilevel regression modeling was used to test for group differences in the change in self-rated health survey scores over time from baseline over the post-operative period. The hierarchical linear modeling approach has a number of advantages over traditional repeated measures approaches for modeling change over time, including allowance for missing data and for varying measurement times across subjects. Separate models were generated for SF-36, Harris Hip Score and WOMAC scores over two-year and over 5-year post-operative time periods.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Core Decompression (CD) Only | Active comparator | Procedure: Core DecompressionParticipants in this group receive standard care |
| Added Polymethylmethacrylate (PMMA) | Experimental | Procedure: Core Decompression, Procedure: PMMA augmentationParticipants in this group receive standard care with an additional treatment |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Association Research Circulation Osseous (ARCO) Stage I and II ONFH diagnosed using MRI and radiographic imaging
Key exclusion criteria (1 listed)
- pre-existing collapse, subchondral fracture or degenerative changes of the hip
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Core DecompressionCore Decompression | Procedure or surgery | Added Polymethylmethacrylate (PMMA), Core Decompression (CD) Only |
| PMMA augmentationPolymethylmethacrylate (PMMA) augmentation | Procedure or surgery | Added Polymethylmethacrylate (PMMA) |
Primary outcome
Progression Free Survival (PFS)
Time frame: 5 years
Progression Free Survival (PFS) is defined as the length of time (reported in months) following surgery that participants have no signs of radiographic progression of femoral head osteonecrosis. Radiographic progression is defined as any degree of flattening or loss of spherical contour of the femoral head as detected on the radiographs or MRI. Appearance of a subchondral fracture (crescent sign) on radiographs or MRI was also considered a sign of progression.
7 secondary outcomes
Conversion Free Survival (CFS)
Time frame: 5 years
Mean Harris Hip Score (HHS)
Time frame: baseline, 2 years post surgery, 5 years post surgery
Change in Harris Hip Score (HHS)
Time frame: baseline, 2 years post surgery
Mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: baseline, 2 years post surgery, 5 years post surgery
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: baseline, 2 years post surgery
Mean Short Form-36 (SF-36)
Time frame: baseline, 2 years post surgery, 5 years post surgery
Change in Short Form-36 (SF-36)
Time frame: baseline, 2 years post surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2020.
- Individual participant dataSharing planned: No
Related trials for Osteonecrosis
Active, not recruitingObservational study
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Knee Pain Chronic, Osteoarthritis, Knee
Not yet recruiting
DEXA Bone Density Analysis of the CoreHip® Prosthesis System
Primary Osteoarthritis, Cartilage Degeneration
RecruitingPhase 4
E-Type - Early Wear of Polyethylene Liners Used in DMC
Osteoarthritis, Osteonecrosis
Active, not recruitingObservational study
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay
Primary Osteoarthritis, Secondary Osteoarthritis
Recruiting
Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty
Arthritis, Traumatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Core Decompression and PMMA augmentation in people with Osteonecrosis, run by University of Minnesota.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression Free Survival (PFS) (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2020; AzTrials last refreshed its copy on 28 Oct 2026.